These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 8077361)

  • 1. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
    Garnero P; Gineyts E; Riou JP; Delmas PD
    J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.
    Robins SP; Woitge H; Hesley R; Ju J; Seyedin S; Seibel MJ
    J Bone Miner Res; 1994 Oct; 9(10):1643-9. PubMed ID: 7817812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease.
    Delmas PD; Gineyts E; Bertholin A; Garnero P; Marchand F
    J Bone Miner Res; 1993 May; 8(5):643-8. PubMed ID: 8511992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
    Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD
    J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases.
    Arbault P; Grimaux M; Pradet V; Preaudat C; Seguin P; Delmas PD
    Bone; 1995 Apr; 16(4):461-7. PubMed ID: 7605707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
    Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
    J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.
    Uebelhart D; Schlemmer A; Johansen JS; Gineyts E; Christiansen C; Delmas PD
    J Clin Endocrinol Metab; 1991 Feb; 72(2):367-73. PubMed ID: 1991806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.
    Garnero P; Delmas PD
    J Clin Endocrinol Metab; 1993 Oct; 77(4):1046-53. PubMed ID: 8104954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.
    Uebelhart D; Gineyts E; Chapuy MC; Delmas PD
    Bone Miner; 1990 Jan; 8(1):87-96. PubMed ID: 2106358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment.
    Bonde M; Qvist P; Fledelius C; Riis BJ; Christiansen C
    J Clin Endocrinol Metab; 1995 Mar; 80(3):864-8. PubMed ID: 7883844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia.
    Body JJ; Delmas PD
    J Clin Endocrinol Metab; 1992 Mar; 74(3):471-5. PubMed ID: 1740478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different responses of free and peptide-bound cross-links to vitamin D and calcium supplementation in elderly women with vitamin D insufficiency.
    Kamel S; Brazier M; Rogez JC; Vincent O; Maamer M; Desmet G; Sebert JL
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3717-21. PubMed ID: 8855828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of bone disease using isomerized and racemized fragments of type I collagen.
    Cloos PA; Fledelius C; Christgau S; Christiansen C; Engsig M; Delmas P; Body JJ; Garnero P
    Calcif Tissue Int; 2003 Jan; 72(1):8-17. PubMed ID: 12384813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
    Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
    J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a monoclonal antibody to urinary degradation products from the C-terminal telopeptide alpha 1 chain of type I collagen. Application in an enzyme immunoassay and comparison to CrossLaps ELISA.
    Fledelius C; Kolding I; Qvist P; Bonde M; Hassager C; Reginster JY; Hejgaard J; Frøokiaer H; Christiansen C
    Scand J Clin Lab Invest; 1997 Feb; 57(1):73-83. PubMed ID: 9127460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
    Garnero P; Shih WJ; Gineyts E; Karpf DB; Delmas PD
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1693-700. PubMed ID: 7989477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?
    Hamdy NA; Papapoulos SE; Colwell A; Eastell R; Russell RG
    Bone Miner; 1993 Jul; 22(1):1-8. PubMed ID: 8219934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.